Chemomab Therapeutics LTD. (CMMB) — SEC Filings

Q: What are the key financial highlights for Chemomab Therapeutics LTD.?

Key financial highlights for Chemomab Therapeutics LTD. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: What is the investment thesis for CMMB?

The investment thesis for CMMB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings filed by Chemomab Therapeutics LTD..

Q: Who are the key executives at Chemomab Therapeutics LTD.?

Key executives at Chemomab Therapeutics LTD. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Chemomab Therapeutics LTD. stock?

Risk factors for Chemomab Therapeutics LTD. (CMMB) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Chemomab Therapeutics LTD.?

Forward-looking statements and predictions from Chemomab Therapeutics LTD. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Chemomab Therapeutics LTD.. Recent 6-K filing on Nov 21, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Chemomab Therapeutics LTD. on SEC EDGAR

Overview

Chemomab Therapeutics LTD. (CMMB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Aug 22, 2025: Chemomab Therapeutics Ltd. announced on August 22, 2025, that it will implement a ratio adjustment for its American Depositary Shares (ADSs) relative to its ordinary shares. The specific details of this ratio adjustment were not disclosed in this filing.

Sentiment Summary

Across 30 filings, the sentiment breakdown is: 2 bullish, 28 neutral. The dominant filing sentiment for Chemomab Therapeutics LTD. is neutral.

Filing Type Overview

Chemomab Therapeutics LTD. (CMMB) has filed 23 6-K, 2 20-F, 3 SC 13D/A, 2 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (30)

6-K Filing — 6-K · Nov 21, 2025
Chemomab Therapeutics Announces ADS Ratio Adjustment — 6-K · Aug 22, 2025 Risk: low
Chemomab Therapeutics Ltd. announced on August 22, 2025, that it will implement a ratio adjustment for its American Depositary Shares (ADSs) relative to its ord
Chemomab Therapeutics Ltd. Files Form 6-K — 6-K · Aug 14, 2025 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on August 14, 2025, reporting on its activities for the month of August 2025. The company, previously known as Anchi
Chemomab Therapeutics Ltd. Enters Sales Agreement — 6-K · Jul 25, 2025 Risk: medium
On July 25, 2025, Chemomab Therapeutics Ltd. entered into a Sales Agreement with LifeSci Capital, LLC. This agreement allows Chemomab to offer and sell its Amer
Chemomab Therapeutics Ltd. Holds Annual Shareholder Meeting — 6-K · Jul 1, 2025 Risk: low
Chemomab Therapeutics Ltd. held its annual general shareholders meeting on July 1, 2025. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancel
Chemomab Therapeutics Files 6-K for Shareholder Meeting — 6-K · May 27, 2025 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on May 27, 2025, to furnish a Notice and Proxy Statement for its upcoming annual general meeting of shareholders. Th
Chemomab Therapeutics Reports Q1 2025 Results — 6-K · May 15, 2025 Risk: medium
Chemomab Therapeutics Ltd. announced its first quarter 2025 financial results and provided a corporate update on May 15, 2025. The company, formerly known as An
Chemomab Therapeutics Announces CMO Departure, Appoints Interim — 6-K · Apr 15, 2025 Risk: medium
Chemomab Therapeutics Ltd. announced on April 15, 2025, the departure of its Chief Medical Officer, Dr. Matthew Frankel. Concurrently, Dr. David M. Weiner, MD,
Chemomab Therapeutics Files 20-F, Reports Capital Losses — 20-F · Apr 4, 2025 Risk: medium
Chemomab Therapeutics Ltd. filed its 20-F report for the fiscal year ending December 31, 2024. The company, formerly known as Anchiano Therapeutics Ltd. and Bio
Chemomab Therapeutics Reports Positive Phase 2 Nebokitug PSC Trial Results — 6-K · Mar 27, 2025 Risk: medium
On March 27, 2025, Chemomab Therapeutics Ltd. announced positive results from the open-label extension of its Phase 2 trial for Nebokitug in Primary Sclerosing
Chemomab Therapeutics Files 6-K with Prospectus Supplement Details — 6-K · Mar 20, 2025 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on March 20, 2025, reporting on a prospectus supplement filed on November 15, 2024, under a Sales Agreement with Rot
Chemomab Therapeutics Reports 2024 Financials & Update — 6-K · Mar 3, 2025 Risk: medium
Chemomab Therapeutics Ltd. announced its financial results for the year ended and fourth quarter of 2024 on March 3, 2025. The company, formerly known as Anchia
Chemomab Therapeutics Clears FDA Path for Nebokitug — 6-K · Feb 19, 2025 Risk: medium
On February 19, 2025, Chemomab Therapeutics Ltd. announced the successful completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (F
Adi Mor Amends Chemomab Therapeutics Stake — SC 13D/A · Nov 29, 2024 Risk: medium
Adi Mor has amended their Schedule 13D filing for Chemomab Therapeutics Ltd. on November 29, 2024. This filing indicates a change in the beneficial ownership of
SC 13G Filing — SC 13G · Nov 21, 2024
Chemomab Therapeutics Ltd. Holds Special Shareholder Meeting — 6-K · Nov 18, 2024 Risk: low
Chemomab Therapeutics Ltd. held a special general shareholders meeting on November 18, 2024, to discuss and vote on certain matters. The company, formerly known
Chemomab Therapeutics Q3 2024 Financial Results Filed — 6-K · Nov 14, 2024 Risk: low
Chemomab Therapeutics Ltd. announced its third quarter 2024 financial results on November 14, 2024. The company, formerly known as Anchiano Therapeutics Ltd. an
Chemomab Therapeutics Calls Special Shareholder Meeting — 6-K · Oct 11, 2024 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on October 11, 2024, to furnish a Notice and Proxy Statement for a special general meeting of its shareholders. The
OrbiMed Files 13D/A Amendment for Chemomab Therapeutics — SC 13D/A · Sep 16, 2024 Risk: medium
OrbiMed Israel BioFund GP Limited Partnership, through its group members Carl L. Gordon and Erez Chimovits, has filed an amendment (No. 4) to its Schedule 13D c
Chemomab Therapeutics Files Form 6-K — 6-K · Aug 21, 2024 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on August 21, 2024, reporting on its activities for the month of August 2024. The company, formerly known as Anchian
SC 13G Filing — SC 13G · Aug 20, 2024
Chemomab Therapeutics Ltd. Files 6-K, Details Former Names — 6-K · Jul 25, 2024 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on July 25, 2024, reporting information as a foreign private issuer. The filing indicates the company was formerly k
Chemomab Therapeutics Holds Annual Shareholder Meeting — 6-K · Jun 12, 2024 Risk: low
Chemomab Therapeutics Ltd. (the "Company") held its annual general shareholders meeting on June 10, 2024. The company, formerly known as Anchiano Therapeutics L
Chemomab Therapeutics Q1 2024 Update — 6-K · May 9, 2024 Risk: low
Chemomab Therapeutics Ltd. announced its first quarter 2024 financial results and provided a corporate update on May 9, 2024. The company, formerly known as Anc
Chemomab Therapeutics Files 6-K with Press Release — 6-K · May 8, 2024 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on May 8, 2024, to furnish a press release dated May 8, 2024. The press release is titled "Chemomab Therape". The co
Chemomab Therapeutics Files Shareholder Meeting Notice — 6-K · May 3, 2024 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on May 3, 2024, to furnish a Notice and Proxy Statement for its upcoming annual general meeting of shareholders. The
Chemomab Therapeutics Files 20-F for FY2023 — 20-F · Mar 28, 2024 Risk: medium
Chemomab Therapeutics Ltd. filed its 20-F for the fiscal year ending December 31, 2023. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell
OrbiMed Files 13D/A Amendment for Chemomab Therapeutics — SC 13D/A · Mar 11, 2024 Risk: medium
OrbiMed Israel BioFund Limited Partnership, along with Carl L. Gordon and Erez Chimovits, filed an amendment (No. 3) to their Schedule 13D on March 11, 2024, co
Chemomab Therapeutics Reports 2023 Financials & Corporate Update — 6-K · Mar 7, 2024 Risk: low
Chemomab Therapeutics Ltd. announced its financial results for the year ended and fourth quarter of 2023 on March 7, 2024. The company, formerly known as Anchia
Chemomab Completes CM-101 PSC Trial Enrollment, Topline Data Mid-2024 — 6-K · Jan 3, 2024
Chemomab Therapeutics Ltd. announced on January 3, 2024, the successful completion of patient enrollment for its CM-101 Phase 2 clinical trial targeting Primary

Risk Profile

Risk Assessment: Of CMMB's 26 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Dr. Matthew Frankel
Dr. David M. Weiner, MD
Adi Mor
Carl L. Gordon
Erez Chimovits

Top Tags

shareholder-meeting (6) · corporate-governance (5) · financial-results (5) · corporate-update (5) · sec-filing (5) · foreign-private-issuer (4) · biotech (4) · regulatory-filing (3) · proxy-statement (3) · filing (3)

Key Numbers

Filing Date: 20250814 — Date the report was filed with the SEC.
Reporting Period End Date: 20250630 — The period the report pertains to.
Capital Losses: $14.2B — Significant losses reported for the fiscal year ending 12/31/2024, requiring a valuation allowance.
Fiscal Year End: 20241231 — The period covered by the 20-F filing.
SEC File Number: 001-38807 — Identifies the company's filing with the SEC.
Amendment Number: 3 — Indicates this is the third update to the filing.

Frequently Asked Questions

What are the latest SEC filings for Chemomab Therapeutics LTD. (CMMB)?

Chemomab Therapeutics LTD. has 30 recent SEC filings from Jan 2024 to Nov 2025, including 23 6-K, 3 SC 13D/A, 2 20-F. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CMMB filings?

Across 30 filings, the sentiment breakdown is: 2 bullish, 28 neutral. The dominant sentiment is neutral.

Where can I find Chemomab Therapeutics LTD. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Chemomab Therapeutics LTD. (CMMB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Chemomab Therapeutics LTD.?

Financial highlights for Chemomab Therapeutics LTD. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for CMMB?

Investment thesis data for CMMB will be available once enriched filings are processed.

Who are the key executives at Chemomab Therapeutics LTD.?

Key executives identified across Chemomab Therapeutics LTD.'s filings include Dr. Matthew Frankel, Dr. David M. Weiner, MD, Adi Mor, Carl L. Gordon, Erez Chimovits.

What are the main risk factors for Chemomab Therapeutics LTD. stock?

Of CMMB's 26 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 15 low-risk.

What are recent predictions and forward guidance from Chemomab Therapeutics LTD.?

Forward guidance and predictions for Chemomab Therapeutics LTD. are extracted from SEC filings as they are enriched.